Abstract Number: 0141 • ACR Convergence 2024
The Effect of Systemic Immunosuppressive Therapies on Cardiovascular Risk in Psoriatic Arthritis Patients
Background/Purpose: Evidence demonstrates an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among psoriatic arthritis (PsA) patients. However, the relationship between immunosuppressive therapies and the development of ASCVD remains unclear.…Abstract Number: 0482 • ACR Convergence 2024
Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis
Background/Purpose: CV disease is leading cause of morbidity and mortality in RA, largely due to endothelial dysfunction.1. Endothelial function is barometer of total cardiovascular risk while…Abstract Number: 0807 • ACR Convergence 2024
Evaluating Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus (SLE) and SLE Subgroups: Additional Risks Associated with Cardiovascular Events
Background/Purpose: Systemic Lupus Erythematosus (SLE) presents substantial risks for both maternal cardiovascular events (CVEs) and adverse pregnancy outcomes, yet, the influence of maternal CVEs on…Abstract Number: 1119 • ACR Convergence 2024
Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis
Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.Methods: This is a…Abstract Number: 1557 • ACR Convergence 2024
Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis
Background/Purpose: Patients with systemic sclerosis (SSc) have increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) caused by systemic inflammation, and vascular impairment. To date,…Abstract Number: 2009 • ACR Convergence 2024
Risk of Incident Gout and Cardiovascular Events Within 120 Days of Incident Gout with the Use of Insulin Glargine, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Veterans with Type 2 Diabetes
Background/Purpose: Previous studies compared the risk of gout with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus glucagon-like peptide-1 receptor agonists (GLP1-RA), including exendin-4 based GLP1-RA (exenatide and lixisenatide). Synthetic…Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…Abstract Number: 0143 • ACR Convergence 2024
Behavioral Factors and Chronic Conditions Associated with Rheumatoid Arthritis, KNHANES 2010 to 2021
Background/Purpose: Rheumatoid arthritis (RA) is associated with multiple genetic and environmental factors. In terms of environmental, dietary and lifestyle factors, there have been discrepancies on…Abstract Number: 0487 • ACR Convergence 2024
The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…Abstract Number: 0841 • ACR Convergence 2024
Clinical and Biologic Predictors of Thrombosis in Persistently Antiphospholipid Antibody Positive Patients: Prospective Analysis of the International APS ACTION Clinical Database and Repository (“Registry”)
Background/Purpose: There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). The APS…Abstract Number: 1133 • ACR Convergence 2024
Relationship Between Nail Psoriasis Severity Index (NAPSI) and Cardiovascular Risk Assessed by Eight Cardiovascular Risk Calculators
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, inflammatory, and immune-mediated disease that affects up to 30% of psoriasis (PsO) patients. Nail psoriasis affects 80% of…Abstract Number: 1567 • ACR Convergence 2024
Systemic Sclerosis Is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Perfusion and Increased Fibrosis
Background/Purpose: Primary cardiac involvement in systemic sclerosis (SSc) is heterogenous, poorly defined and associated with significant cardiac morbidity and mortality. The underlying mechanism is not…Abstract Number: 2038 • ACR Convergence 2024
Nationwide Analysis of Adult Hospitalizations with Rheumatologic Conditions and Spontaneous Coronary Artery Dissection
Background/Purpose: Rheumatic diseases have a higher risk of cardiovascular events, particularly those related to atherothrombosis which represents the leading cause of premature mortality in most of…Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…Abstract Number: 0147 • ACR Convergence 2024
Clinical Characteristics and Biomarkers Associated with Detectable High-Sensitivity Cardiac Troponin in Patients with Rheumatoid Arthritis
Background/Purpose: General population-based cardiovascular (CV) risk estimators are known to underestimate CV risk in RA. High-sensitivity cardiac troponin T (hs-cTnT), typically measured during a work-up…
- 1
- 2
- 3
- …
- 31
- Next Page »